证券时报·数据宝统计显示，迈瑞医疗今日收盘价为199.82元，上涨2.07%，日换手率为0.92%，成交额 为22.23亿元，全天主力资金净流入1.24亿元，近5日该股累计下跌1.27%，近5日资金合计净流出2602.50 万元。 两融数据显示，该股最新融资余额为38.93亿元，近5日增加8935.87万元，增幅为2.35%。 据天眼查APP显示，深圳迈瑞生物医疗电子股份有限公司成立于1999年01月25日，注册资本 121244.1394万人民币。（数据宝） 12月12日迈瑞医疗大宗交易一览 （文章来源：证券时报网） 迈瑞医疗12月12日大宗交易平台出现一笔成交，成交量3.41万股，成交金额681.39万元，大宗交易成交 价为199.82元。该笔交易的买卖双方均为机构专用席位。 进一步统计，近3个月内该股累计发生14笔大宗交易，合计成交金额为1.95亿元。 | 成交量（万 | 成交金额（万 | 成交价格 | 相对当日收盘折溢价 | 买方营业 | 卖方营业 | | --- | --- | --- | --- | --- | --- | | 股） | 元） | （元） | （%） | 部 | 部 | | 3.4 ...

Core Points - The article discusses the performance of the Chuangye 50 ETF (159682) as of December 12, noting a 0.48% increase, with a trading volume of 203 million yuan [1] - The article highlights the performance of key stocks within the ETF, including declines in stocks like Ningde Times and Sunshine Power, while others like Xinyisheng and Shenghong Technology saw gains [1] - The Chuangye 50 ETF has a performance benchmark of the ChiNext 50 Index, managed by Invesco Great Wall Fund Management, with a return of 46.75% since its inception on December 23, 2022, and a 2.02% return over the past month [1] Stock Performance - As of the midday close, Ningde Times decreased by 0.24%, while Xinyisheng increased by 2.63% [1] - Other notable stock performances include a 1.98% increase for Shenghong Technology and a 0.57% increase for Dongfang Caifu [1] - The ETF's performance reflects mixed results among its top holdings, indicating varying market conditions for these companies [1] Fund Management - The Chuangye 50 ETF is managed by Invesco Great Wall Fund Management, with fund managers Wang Yang and Zhang Xiaonan [1] - The fund's performance since inception and recent monthly returns suggest a strong management strategy, contributing to its overall growth [1]

Group 1 - The core viewpoint is that the US economy is expected to maintain moderate growth next year, supported by factors such as Federal Reserve interest rate cuts and AI investments, while remaining strategically bullish on US stocks but cautious of structural differentiation and short-term risks in Q1 [1] - For the Hong Kong stock market outlook, it is anticipated that the market will shift from valuation-driven to profit growth-driven, with valuation expansion likely to weaken but liquidity remaining supportive [1] - The combination of profit-driven growth and liquidity support is expected to emerge by 2026, with new supply creating new demand as a new driving force for the Hong Kong stock market [1] Group 2 - The technology sector in the US stock market is expected to become more rational, with AI remaining a key driver, and the regulatory environment being favorable for mergers and acquisitions [1] - The AI advancements are projected to continue driving revenue and valuation recovery in the Chinese internet sector's cloud business [1] - The domestic pharmaceutical and innovative drug sectors are likely to benefit from a resurgence in mergers and acquisitions by large multinational pharmaceutical companies, as well as an increase in BD transactions [1] Group 3 - The automotive industry is expected to see flat or slightly declining sales next year, with current market sentiment being sufficiently pessimistic, presenting an opportunity to gradually accumulate stocks of companies with high earnings growth certainty [2] - The consumption sector's recovery remains uneven, suggesting a strategy of "anchoring on earnings while leveraging growth" for investment [2] - The education sector is viewed positively for its resilient growth and expansion opportunities [2] Group 4 - Recommended stocks for Q1 next year include: Alphabet (GOOGL.US), Meta (META.US), Netflix (NFLX.US), Tencent Holdings (00700), Alibaba (BABA.US), Bilibili (BILI.US), Hansoh Pharmaceutical (03692), CanSino Biologics-B (02162), Innovent Biologics (01801), and others [2]

Group 1 - The core viewpoint of the report is that Asian stock markets have risen approximately 25% this year, driven by a revaluation of price-to-earnings ratios, with strong support from a resilient macro environment and robust corporate earnings momentum [1] - The report highlights that South Korea and China maintain strong momentum, while India's stock market continues to reach new highs. Japan remains attractive amid accelerated reforms, and the Australian market shows steady performance [1] - The report anticipates that by mid-2026, the reality of AI returns will be tested, with a peak in the US dollar exchange rate, which will help Asian and emerging markets outperform the broader market [1] Group 2 - In China, strong earnings momentum is expected to drive a 15% upside potential, with a consensus forecast of 16% earnings growth per share by 2026. The private sector and high-tech manufacturing are expected to lead this growth [2] - The report identifies key sectors for 2026, including alternative energy (lithium batteries, solar), automotive, beauty, healthcare, industrial automation, internet technology, and semiconductors, while maintaining a cautious stance on materials and durable consumer goods [2] Group 3 - The report recommends several thematic stocks for 2026, including Tencent, CATL, Sungrow Power Supply, Mindray, Yili, Geely, Galaxy Entertainment, Huahai Pharmaceutical, Yihua Healthcare, and InnoCare Pharma [3]

Group 1: Economic Outlook - The U.S. economy is expected to maintain moderate growth in the coming year, supported by factors such as Federal Reserve interest rate cuts and AI investments [1] - The Hong Kong stock market is anticipated to shift from valuation-driven to profit growth-driven, with a projected earnings growth rate of 6% to 10% for the Hang Seng Index [1] Group 2: Market Dynamics - The valuation expansion in the Hong Kong market may weaken, but liquidity will remain supportive, leading to a new supply creating new demand [1] - The dual liquidity easing in both China and the U.S. is expected to increase foreign and southbound capital supply, translating into new demand for Hong Kong stocks [1] Group 3: Sector Analysis - The U.S. tech sector is expected to become more rational, with AI continuing to be a key driver, while the regulatory environment will favor mergers and acquisitions [2] - The domestic pharmaceutical and innovative drug sectors are likely to benefit from a resurgence in M&A activity from large multinational companies [2] - The automotive sector is projected to see flat or slightly declining sales, presenting opportunities to gradually accumulate stocks of companies with high earnings growth certainty [2] Group 4: Recommended Stocks - Top stock picks for the first quarter of next year include Alphabet (GOOGL.US), Meta (META.US), Netflix (NFLX.US), Tencent Holdings (00700), Alibaba (BABA.US), and others [3]

该公司成立于2005年6月，经营范围包括第一类医疗器械生产、第二类医疗器械销售、智能机器人的研 发等，现由深圳迈瑞科技控股有限责任公司及上述新增股东共同持股。 来源：中国能源网 天眼查App显示，近日，武汉迈瑞科技有限公司发生工商变更，史鹏卸任法定代表人、执行董事、经 理，韩乐接任法定代表人、经理并担任董事，新增迈瑞医疗（300760）为股东，同时，注册资本由3亿 人民币增至23亿人民币，增幅约667%。 ...

11 December 2025 | 7:23AM CST Equity Research China Healthcare: Nov 2025 China hospital equipment bidding: Higher-than-expected yoy growth; lifting base case assumption We note that, while we have made a modest upward revision to our industry outlook, we maintain our earnings forecasts for our two covered companies, Mindray and United Imaging. Our existing estimates already incorporate the assumption that both companies will outperform the industry, and this latest industry-level adjustment does not alter o ...

Core Insights - China is a significant market for global medical AI solutions, benefiting from technological advancements, high-quality medical data accumulation, supportive national policies, and growing market demand, leading to rapid growth in AI applications in healthcare [1][4]. Market Size and Growth - The market size for medical AI solutions in China is projected to grow from 9.1 billion yuan in 2021 to 16.4 billion yuan in 2024, with L1 solutions increasing from 5.8 billion yuan to 9.4 billion yuan, L2 solutions from 3.3 billion yuan to 6.9 billion yuan, and L3 solutions at 0.1 billion yuan [1][4]. - By 2025, the market size is expected to reach 18.2 billion yuan, with L1 solutions at 9.8 billion yuan, L2 solutions at 7.8 billion yuan, and L3 solutions at 0.6 billion yuan [1][4]. Industry Definition and Applications - Medical AI solutions utilize AI technologies such as machine learning, deep learning, natural language processing, and big data analysis to enhance various medical processes, including diagnosis, treatment, drug development, and hospital management [2][3]. - The industry is evolving from L1 and L2 solutions, which provide supportive insights, to L3 and L4 autonomous agents capable of executing tasks independently [2][3]. Industry Development Status - The integration of general large model capabilities with medical knowledge bases is driving the transition of medical AI solutions towards higher levels of autonomy [3][4]. - The global market for medical AI solutions is expected to grow from 23.2 billion yuan in 2021 to 40 billion yuan in 2024, with L1 solutions increasing from 13.9 billion yuan to 21.1 billion yuan, L2 solutions from 9.3 billion yuan to 18.7 billion yuan, and L3 solutions at 0.2 billion yuan [4]. Industry Chain - The medical AI solutions industry chain includes upstream data supply, hardware providers (chips, servers), cloud services, operating systems, and algorithms, with midstream companies providing AI solutions and downstream applications in healthcare institutions, pharmaceutical companies, and individual patients [5]. Policy Environment - The Chinese government has prioritized the application of AI in healthcare, implementing policies to support AI in medical diagnosis, health management, and insurance regulation, which are expected to accelerate the development of AI in healthcare [5]. Competitive Landscape - The industry features a competitive landscape with local giants, vertical startups, and multinational companies. Key players include iFlytek Medical, Baidu, United Imaging, CloudWalk, Weining Health, and Mindray Medical [7]. - iFlytek Medical is a leading company in the AI healthcare sector, leveraging its large model to empower various healthcare stakeholders and has developed comprehensive AI solutions for hospitals and primary care institutions [9][11]. Revenue Structure of Key Players - iFlytek Medical reported a revenue of 299 million yuan in the first half of 2025, with contributions from various solutions: 84 million yuan from primary care solutions, 58 million yuan from regional solutions, 53 million yuan from hospital solutions, and 104 million yuan from patient management services [11]. - The company aims to build a robust B-end ecosystem to strengthen its commercial channels [9]. Future Trends - The development of the medical AI industry will be driven by a combination of technology, data, scenarios, and regulation, leading to a more mature, deeper, and broader market landscape [12].

[Table_Invest] 评级： 增持 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 江珅(分析师) | 021-23185638 | jiangshen@gtht.com | S0880525090001 | | 赵峻峰(分析师) | 0755-23976629 | zhaojunfeng@gtht.com | S0880519080017 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | 本报告导读： 请务必阅读正文之后的免责条款部分 股 票 研 究 政策拉动国内市场有效复苏，医疗设备招 采保持快速增长 投资要点： [Table_Report] 相关报告 医疗器械《政策拉动国内市场有效复苏，设备类 企业迎来业绩拐点》2025.11.11 医疗器械《政策资本多重共振，脑机商业化有望 加速》2025.10.22 医疗器械《医疗设备招投标规模保持增长，25 年 新一轮医疗设备更新有望来临》2025.10.13 医疗器械《设备更新政策持续落 ...

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]